SpePharm Buys Drug Rights from TopoTarget, Raises New VC
SpePharm Holding NV, an Amsterdam-based acquirer and marketer of hospital drugs to the pan-European market, has acquired the global rights (exclusing North and South America) to Savene, a drug compound used to treat blood stream leakages, from TopoTarget AS. To finance the deal, SpePharm has raised €7 million in new VC funding from return backers TVM Capital, Signet Healthcare and Paul Capital Healthcare. It also secured €4 million in debt from Paladin Labs Inc.
5 March 2010•5 mins read
